Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB

FRIDAY, Sept. 16, 2022 -- For patients with extensively drug-resistant (XDR) tuberculosis, the overall risk-benefit ratio seems to favor patients receiving the bedaquiline-pretomanid-linezolid regimen with linezolid at a dose of 600 mg for 26 weeks,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news